Member Info for hahahehehoho

Winner, if anything , instead of complaining now would be the time to accumulate more brh. If a company has the correct product and timing, impatient people will always be doubtful and fearful regardless. You mention ncyt , but I don't hold it anymore but I remember ncyt at 70p on lse ....and it had it full share of complainers and whiners......

I hear you winner. Let's see what the trial results bring first. Even if this was valued at £150m now, honestly, I'd still buy this. Risky , but unique technology makes it worth the risk.

Isthisawinner, love your urgency but covid looks like it will be here for years to come. Chill. Brh have the correct two part diagnostic product coming into the right time. You are also forgetting this has global scale too, even for developing countries .

91, fast accurate cheap testing is the future going in to 2021 and beyond. Unlike the saturated PCR market, this market is currently open and there for the taking for one to dominate.. It is however, important to be patient and get the product right and not release misleading statements. For example , who is going to trust TT Electronics now? Who is going to buy from Deepverge, with a system so complicated and cumbersome?

Brh are on track to developing the right product at the right time . Have patience.

I'd rather this stay low profile tbh as it is cool here and i'm getting more money in December to invest here. As long as SP is under £1 by then I'm happy ;-p

Btw, Brh could always do it the TTG way and tell lies to temporarily pump up the SP. Instead of Trevor doing the talking we should I'll let Paraytec's breakthrough tech do the talking. Moonshot will come, be patient

It has been developed primarily in house with professor Smythe and Sheffield Uni. Whatever business decision is probably made is made with the forementioned. As to your questions, perhaps Trevor or Carl could answer those better but as it is , the two stage test we already have is very adaptable and more promising and potentially better than anything currently developing on the market so far. Whether this equates to hundreds in millions on profits next year, this is down to Trevor , his contacts and most importantly ....timing.

I am not interested in market capital here or how tiny BRH compares to others. I am just interested in Paraytec's flexible and adaptable use and in how it may be superior to others in the market. Here is what is remarkable and why they have a really good shot at first capturing Moonshot and then the global market:

- CAPTURE and SIGNAL is adaptable to paper testing, etc but at a cost of sensitivity.

-CAPTURE and SIGNAL along with handheld Actipix light sensor could be used in live environments such as kitchens, public transportation, hospitals, etc, etc Just spray CAPTURE solution on the surface, wait, then use an adapted handheld sensor to detect luminescent particles to appear.

- iAbra/ TTG , Deepverge, etc... are COMPLETELY reliant on their technology. We have a two-stage test that if the light sensor machine breaks down, we can still use the first stage test to identify the virus (I assume this will be a pregnancy test similar to Mologics or Avactas). If a cruise ship is halfway between the Atlantic and their machines break down, how are iabra/ Deepverge going to test for the virus and how is this applicable to countries in South America India, or Africa where power is unreliable? Cruise liners / developing countries are much better off buying a two-stage test like ours as I assume it would be cheaper and simpler too.

- Paraytec's light sensing technology is already developed and established and all it needs is miniaturizing. With AI companies like DV/iabra they are creating new technology from scratch and I foresee many debugging and crash issues with their technology.

- Usually, If 10-15 min result POC tests show a positive result for the virus, the person will need a PCR test which can take up to a couple of hours. Depending on sensitivity and specificity we may not need PCR if Actipix comes close to the necessary specifications. We have a two-stage test which is complimentary.

- Along with Actipix, the state of a COVID infection can be detected in a person, whether it is at the start, middle, or end. I am not sure if this can be done in a single test but surely it can be done over several over a course of a few days. Hopefully, this can be confirmed later

Exciting times for next-generation testing. #BRH

I may get pillared for it, but there is a realistic probability of a placing or loan of some sorts after live trials are successfully completed. However, it must be noted we still own 100% IP similar to Avacta and Novacyt. I also assume we don't need to share revenue like ODX or be anything like a second party seller such as DVRG (breathalyzers)

I'd also like to add the first stage test (CAPTURE) could be used as a portable instant home test. There are lots of options and as Carl said CAPTURE can be adapted to a paper test too (albeit sacrificing sensitivity)

Regulator thanks for your apology on your "full category 3 labs" slipup. Hope that has cleared things up for confused new investors.

For new investors, yes this company has had a rough ride in the past, but you need to realize Paraytec have created a two stage test unlike anything on the global market. We have developed our own aptamer and along with using our existing light sensing technology this would indicate what stage of infection a patient is in. This is key to understanding how effective covid medicines are responding in patients and also key to quarantining people at necessary time periods. This essentially cuts down on wasted time for those quarantined , and brings people to live their lives normally and quickly.

iabra ad TT electronics are doing a similar project but without biochemistry and are just using a ultra high res microscope and AI, this has subsequently seen TTGs sp indicate their share in he project (50%??) was worth 220m pounds at one point. Since their last RNS has been released it has been discredited by the scientific community and seen the SP down again.

For more info and questions ask the lead scientist: https://twitter.com/carlsmythe/

I also agree. Clinical trials have probably started and only once that is completed with approvals will Moonshot buy in with £xxxm. It's a unique test nonetheless which can detect stage of infection which no other test can do and I've always ranted brh have have full intellectual property which is hugely important.

Couldn't have released a better timed RNS when full lockdown is upon the UK. Even better for Paraytec is that they own full IP and have developed everything for themselves a bit like Avacta

Sold out out all my ncyt for brh this week. Ncyt will always be important but PCR isn't doing anything to stop the virus spreading . Companies like paraytec and avacta are next generation testing stocks which might be more effective to slow spread

Raider, there are plenty of covid patients in the uk now and approvals are being sought as we speak. I don't think much longer tbh. It does seem that we are ahead of Oxford however

They have a unique 2 stage test with the secondary test based on light sensor technology which can detect stage of infection. Based on the exaggerations of ttg recently (which has a partnership with iabra) added £220m on to its own market cap, this so could go very well, especially since we have developed everything in house here.

"regulation "..."is being sought" as we speak.
We must be close.
And certainly must be close to Moonshot £xxxm contract.

SNG closed 36-37 the day before it announced sng001 phase 2 results a few months ago.

GLR1990, You don't necessarily even need the light detection machine as the solution will change color in the presence of the virus. the machine gives you the extra option of speed and stage of infection, the latter being so important and so unique to anything what is being developed on the market . Everything is super clever, but does Paraytec have an even more super clever business plan?

We know it is a game changer.

But we need to know speed, sensitivity and accuracy concerning the test in real life settings. Product design , business plan, cost and manufacturing strategies are where DVRG slipped up on remember and that went from 75p to 28p .

Either way we'll see a huge sp shift tomorrow I'm sure ;-)

He seems to think ours is superior.